SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

CTPI-2

Item No. 36933

CAS Registry No.:	68003-38-3
Formal Name:	2-[[(4-chloro-3-nitrophenyl) sulfonyl]amino]-benzoic acid
MF:	$C_{13}H_9ClN_2O_6S$
FW:	356.7
Purity:	≥95%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CTPI-2 is supplied as a solid. A stock solution may be made by dissolving the CTPI-2 in the solvent of choice, which should be purged with an inert gas. CTPI-2 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of CTPI-2 in these solvents is approximately 5 and 2 mg/ml, respectively.

Description

CTPI-2 is an inhibitor of the mitochondrial citrate transporter, also known as SLC25A1.[1] It decreases the oxygen consumption rate (OCR) in tumor spheres isolated from patients with non-small cell lung cancer (NSCLC) and inhibits the invasion of lung cancer stem cells *in vitro*. CTPI-2 (50 µM) acts synergistically with cisplatin (Item No. 13119) to reduce the viability of cisplatin-resistant patient-derived NSCLC cells. It reverses increases in body weight, steatosis, and fasting blood glucose levels in a mouse model of high fat diet-induced non-alcoholic fatty liver disease (NAFLD) when administered at a dose of 50 mg/kg.[2]

References

1. Fernandez, H.R., Gadre, S.M., Tan, M., *et al.* The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. *Cell Death Differ.* **25(7)**, 1239-1258 (2018).
2. Tan, M., Mosaoa, R., Graham, G.T., *et al.* Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. *Cell Death Differ.* **27(7)**, 2143-2157 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM